Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 15/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 3/20 | 0.31 |
| ▸ | CA7 | P43166 | 2/20 | 0.31 |
| ▸ | CA4 | P22748 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1801319 | 0.84 | CYP2A6 (0.33) | CA2CA1CA7CA4CA12 | |
| SCHEMBL6152123 | 0.80 | CA2 (0.35) | CA2CA1CA7CA4CA12 | |
| SCHEMBL335048 | 0.79 | CA2 (0.38) | CA2CA1 | |
| SCHEMBL336385 | 0.77 | — | — | |
| SCHEMBL3880729 | 0.75 | LMNA (0.38) | CA2ALDH1A1MAPK1CA1CA7 | |
| SCHEMBL27472507 | 0.70 | — | — | |
| SCHEMBL28451804 | 0.70 | ALDH1A1 (0.38) | ALDH1A1POLBMAPK1SMN1; SMN2 | |
| SCHEMBL7033949 | 0.70 | ALDH1A1 (0.43) | CA2ALDH1A1POLBMAPK1SMN1; SMN2 | |
| SCHEMBL5282730 | 0.69 | CA2 (0.36) | CA2CA1 | |
| SCHEMBL4000892 | 0.68 | CA12 (0.38) | CA2CA1CA12CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7951800-B2 | Anti-infective agents | ABBOTT LABORATORIES, INC. (US) | 2011-05-31 | — | — | US | disclosed |
| US-20100120753-A1 | Anti-Infective Agents | ABBOTT LABORATORIES (US) | 2010-05-13 | — | — | US | disclosed |
| US-7662958-B2 | e.g. N-[3-{1-[(cyclobutyl)amino]-4-hydroxy-2-oxo-1,2-dihydro-quinolin -3-yl}-1,1-dioxo-1,4-dihydro-1 lambda 6-thieno[2,3-e][1,2,4]thiadiazin-7-yl)methyl]methane-sulfonamide; viricides for infections caused by an RNA-containing virus; hepatitis C virus (HCV) polymerase inhibitor; liver cirrhosis | ABBVIE INC. | 2010-02-16 | — | — | US | disclosed |
| US-20080214528-A1 | ANTI-INFECTIVE AGENTS | ABBVIE INC. | 2008-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214528-A1 | ANTI-INFECTIVE AGENTS | NQO2, RSU1, RRS1 | CA2 3689/4885ALDH1A1 1406/4885POLB 88/4885 |
| US-20100120753-A1 | Anti-Infective Agents | RSU1, NQO2, RRS1 | CA2 3663/4885ALDH1A1 1719/4885POLB 105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.